MoonLake Immunotherapeutics (MLTX) Profit After Tax (2021 - 2026)

MoonLake Immunotherapeutics' Profit After Tax history runs 6 years deep, the most recent figure standing at -$69.7 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 71.87% year-over-year to -$69.7 million; the TTM figure through Mar 2026 stood at -$261.9 million (down 78.11% YoY), while the FY2025 annual figure was -$230.3 million, down 93.65% from the prior year.
• Profit After Tax was -$69.7 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$65.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$7.4 million in Q4 2023 to a low of -$70.7 million in Q3 2025.
• Historically, Profit After Tax has averaged -$31.1 million across 5 years, with a median of -$17.4 million in 2022.
• Biggest YoY gain for Profit After Tax was 68.11% in 2022; the steepest drop was 4415.6% in 2022.
• A 5-year view of Profit After Tax shows it stood at -$17.1 million in 2022, then soared by 56.53% to -$7.4 million in 2023, then sank by 513.23% to -$45.6 million in 2024, then slumped by 43.47% to -$65.4 million in 2025, then declined by 6.54% to -$69.7 million in 2026.
• The last three Profit After Tax figures came in at -$69.7 million (Q1 2026), -$65.4 million (Q4 2025), and -$70.7 million (Q3 2025), per Business Quant data.